|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:protease_inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2003
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AE08
|
|
gptkbp:brand
|
gptkb:Reyataz
|
|
gptkbp:CASNumber
|
198904-31-3
|
|
gptkbp:category
|
gptkb:antiviral_drug
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:drugInteraction
|
gptkb:proton_pump_inhibitors
gptkb:rifampin
statins
|
|
gptkbp:eliminationHalfLife
|
6.5 hours
|
|
gptkbp:hasMolecularFormula
|
C38H52N6O7
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
86%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
jaundice
rash
hyperbilirubinemia
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:J05AE
gptkb:163706-06-7
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atazanavir
|